Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer - PubMed (original) (raw)
Comparative Study
doi: 10.1007/s10549-014-3085-5. Epub 2014 Aug 8.
Affiliations
- PMID: 25104443
- DOI: 10.1007/s10549-014-3085-5
Comparative Study
Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer
Felix Y Feng et al. Breast Cancer Res Treat. 2014 Aug.
Abstract
Sustained locoregional control of breast cancer is a significant issue for certain patients. Inhibition of PARP1 is a promising strategy for radiosensitization (RS). We sought to optimize therapy with PARP1 inhibition and radiation (RT) by establishing the most effective treatment schedule, degree of PARP1-mediated RS, and identify early biomarkers predictive of efficacy in breast cancer models. Using clonogenic survival assays, we assessed intrinsic radiosensitivity and RS induced by PARP1 inhibition in breast cancer cell lines. Potential biomarkers of response were evaluated using western blotting, flow cytometry, and immunofluorescence with validation in vivo using tumor xenograft experiments. Across a panel of BC and normal breast epithelial cell lines, the PARP1 inhibitor ABT-888 preferentially radiosensitizes breast cancer (vs. normal) cells with enhancement ratios (EnhR) up to 2.3 independent of intrinsic BC subtype or BRCA mutational status. Concurrent and adjuvant therapy resulted in the highest EnhR of all schedules tested. The degree of RS did not correlate with pretreatment markers of PARP1 activity, DNA damage/repair, or cell cycle distribution. Increases in PARP1 activity 24 h after RT were associated with sensitivity after combination treatment. Findings were confirmed in breast cancer xenograft models. Our study demonstrates that PARP1 inhibition improves the therapeutic index of RT independent of BC subtype or BRCA1 mutational status and that PARP1 activity may serve as a clinically relevant biomarker of response. These studies have led to a clinical trial (TBCRC024) incorporating intratreatment biomarker analyses of PARP1 inhibitors and RT in breast cancer patients.
Similar articles
- PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation.
Michmerhuizen AR, Pesch AM, Moubadder L, Chandler BC, Wilder-Romans K, Cameron M, Olsen E, Thomas DG, Zhang A, Hirsh N, Ritter CL, Liu M, Nyati S, Pierce LJ, Jagsi R, Speers C. Michmerhuizen AR, et al. Mol Cancer Ther. 2019 Nov;18(11):2063-2073. doi: 10.1158/1535-7163.MCT-19-0520. Epub 2019 Aug 14. Mol Cancer Ther. 2019. PMID: 31413177 Free PMC article. - Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.
Luo J, Dai X, Hu H, Chen J, Zhao L, Yang C, Sun J, Zhang L, Wang Q, Xu S, Xu Y, Liu N, Ying G, Wang P. Luo J, et al. J Cancer Res Clin Oncol. 2020 Mar;146(3):721-737. doi: 10.1007/s00432-019-03097-6. Epub 2019 Nov 30. J Cancer Res Clin Oncol. 2020. PMID: 31786739 - Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
Vance S, Liu E, Zhao L, Parsels JD, Parsels LA, Brown JL, Maybaum J, Lawrence TS, Morgan MA. Vance S, et al. Cell Cycle. 2011 Dec 15;10(24):4321-9. doi: 10.4161/cc.10.24.18661. Epub 2011 Dec 15. Cell Cycle. 2011. PMID: 22134241 Free PMC article. - [PARP inhibitors: significant progress in cancer therapy].
Dantzer F, Noel G, Schreiber V. Dantzer F, et al. Bull Cancer. 2011 Mar;98(3):277-90. doi: 10.1684/bdc.2011.1330. Bull Cancer. 2011. PMID: 21459712 Review. French. - Metformin: A Novel Biological Modifier of Tumor Response to Radiation Therapy.
Koritzinsky M. Koritzinsky M. Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):454-64. doi: 10.1016/j.ijrobp.2015.06.003. Int J Radiat Oncol Biol Phys. 2015. PMID: 26383681 Review.
Cited by
- A Theoretical Study of the Interaction of PARP-1 with Natural and Synthetic Inhibitors: Advances in the Therapy of Triple-Negative Breast Cancer.
Turpo-Peqqueña AG, Leiva-Flores EK, Luna-Prado S, Gómez B. Turpo-Peqqueña AG, et al. Curr Issues Mol Biol. 2024 Aug 27;46(9):9415-9429. doi: 10.3390/cimb46090558. Curr Issues Mol Biol. 2024. PMID: 39329910 Free PMC article. - Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma.
Phillipps J, Nassief G, Morecroft R, Adeyelu T, Elliott A, Abdulla F, Vanderwalde A, Park S, Butt O, Zhou A, Ansstas G. Phillipps J, et al. NPJ Precis Oncol. 2024 Sep 5;8(1):187. doi: 10.1038/s41698-024-00684-w. NPJ Precis Oncol. 2024. PMID: 39232122 Free PMC article. - BUB1 Inhibition Sensitizes TNBC Cell Lines to Chemotherapy and Radiotherapy.
Sriramulu S, Thoidingjam S, Siddiqui F, Brown SL, Movsas B, Walker E, Nyati S. Sriramulu S, et al. Biomolecules. 2024 May 25;14(6):625. doi: 10.3390/biom14060625. Biomolecules. 2024. PMID: 38927028 Free PMC article. - Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization.
Zhang Y, Liang L, Li Z, Huang Y, Jiang M, Zou B, Xu Y. Zhang Y, et al. Front Oncol. 2023 Dec 4;13:1295579. doi: 10.3389/fonc.2023.1295579. eCollection 2023. Front Oncol. 2023. PMID: 38111536 Free PMC article. Review. - PARP inhibitors combined with radiotherapy: are we ready?
Sun C, Chu A, Song R, Liu S, Chai T, Wang X, Liu Z. Sun C, et al. Front Pharmacol. 2023 Oct 26;14:1234973. doi: 10.3389/fphar.2023.1234973. eCollection 2023. Front Pharmacol. 2023. PMID: 37954854 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous